TY - JOUR
T1 - Validation of Urinary Charged Metabolite Profiles in Colorectal Cancer Using Capillary Electrophoresis-Mass Spectrometry
AU - Sakurai, Toru
AU - Katsumata, Kenji
AU - Udo, Ryutaro
AU - Tago, Tomoya
AU - Kasahara, Kenta
AU - Mazaki, Junichi
AU - Kuwabara, Hiroshi
AU - Kawakita, Hideaki
AU - Enomoto, Masanobu
AU - Ishizaki, Tetsuo
AU - Nemoto, Yukako
AU - Osaka, Yoshiaki
AU - Nagakawa, Yuichi
AU - Sugimoto, Masahiro
AU - Tsuchida, Akihiko
N1 - Funding Information:
Funding: This research was funded by grants from Yamagata Prefecture and Tsuruoka City, JSPS KAKENHI (grant numbers JP20H05743).
Publisher Copyright:
© 2022 by the authors. Li-censee MDPI, Basel, Switzerland.
PY - 2022/1
Y1 - 2022/1
N2 - This study aimed to validate and reanalyze urinary biomarkers for detecting colorectal cancers (CRCs). We previously conducted urinary metabolomic analyses using capillary electro-phoresis-mass spectrometry and found a significant difference in various metabolites, especially polyamines, between patients with CRC and healthy controls (HC). We analyzed additional samples and confirmed consistency between the newly and previously analyzed data. In total, we included 36 HC, 34 adenoma (AD), and 214 CRC samples, which were used for subsequent analyses. Among the 132 quantified metabolites, 16 exhibited consistent differences in both datasets, which included polyamines, etc. Pathway analyses of the integrated data revealed significant differences in many metabolites, such as glutamine, and metabolites of the TCA and urea cycles. The discrimination ability of the combination of multiple metabolites among the three groups was evaluated, which yielded higher sensitivity than tumor markers. The Mann–Whitney test was employed to evaluate the prognosis predictivity of the assessed metabolites and the difference between the patients with or without recurrence, which yielded 16 significantly different metabolites. Among these 16 metabolites, 11 presented significant prognosis predictivity. These data indicated the potential of metabolite-based discrimination of patients with CRC and AD from HC and prognosis predic-tivity of the monitored metabolites.
AB - This study aimed to validate and reanalyze urinary biomarkers for detecting colorectal cancers (CRCs). We previously conducted urinary metabolomic analyses using capillary electro-phoresis-mass spectrometry and found a significant difference in various metabolites, especially polyamines, between patients with CRC and healthy controls (HC). We analyzed additional samples and confirmed consistency between the newly and previously analyzed data. In total, we included 36 HC, 34 adenoma (AD), and 214 CRC samples, which were used for subsequent analyses. Among the 132 quantified metabolites, 16 exhibited consistent differences in both datasets, which included polyamines, etc. Pathway analyses of the integrated data revealed significant differences in many metabolites, such as glutamine, and metabolites of the TCA and urea cycles. The discrimination ability of the combination of multiple metabolites among the three groups was evaluated, which yielded higher sensitivity than tumor markers. The Mann–Whitney test was employed to evaluate the prognosis predictivity of the assessed metabolites and the difference between the patients with or without recurrence, which yielded 16 significantly different metabolites. Among these 16 metabolites, 11 presented significant prognosis predictivity. These data indicated the potential of metabolite-based discrimination of patients with CRC and AD from HC and prognosis predic-tivity of the monitored metabolites.
KW - Adenoma
KW - Capillary electrophoresis-mass spectrometry
KW - Colorectal cancer
KW - Metabolome
UR - http://www.scopus.com/inward/record.url?scp=85122749544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122749544&partnerID=8YFLogxK
U2 - 10.3390/metabo12010059
DO - 10.3390/metabo12010059
M3 - Article
AN - SCOPUS:85122749544
SN - 2218-1989
VL - 12
JO - Metabolites
JF - Metabolites
IS - 1
M1 - 59
ER -